Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: Validation with FDG-PET and histology

Contrast Media and Molecular Imaging

Volumn 5, Issue 3, 2010, Pages 147-154

  Zheng, Jinzi ^a,b   Allen, Christine ^a,b   Serra, Stefano ^c   Vines, Douglass ^a,b   Charrong, Martin ^d   Jaffray, David A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cancer; Computed tomography (CT); Contrast agent; Inflammation; Liposome; Positron emission tomography (PET)

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOTERIDOL; IODINATED CONTRAST MEDIUM; IOHEXOL; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CELL SUSPENSION; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HISTOLOGY; INFLAMMATION; MALE; NEOPLASM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RABBIT; SCREENING; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; VALIDATION PROCESS; VX 2 CELL STRAIN;

ANIMALS; CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; INFLAMMATION; LIPOSOMES; LIVER NEOPLASMS; LYMPH NODES; MALE; POSITRON-EMISSION TOMOGRAPHY; RABBITS; SIGNAL PROCESSING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77954581939     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.378     Document Type: Article

References (36)

1. Zerhouni E. Medicine. The NIH roadmap. Science 2003; 302(5642): 63-72.
2. Weis SM. Vascular permeability in cardiovascular disease and cancer. Curr Opin Hematol 2008; 15(3): 243-249. (Pubitemid 351509347)
3. Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1992; 1104(1): 95-101.
4. Dams ET, Oyen WJ, Boerman OC, Storm G, Laverman P, Kok PJ, Buijs WC, Bakker H, van der Meer JW, Corstens FH. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 2000; 41(4): 622-630. (Pubitemid 30207737)
5. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008; 99(3): 392-397.
6. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19(4): 424-436.
7. Zheng J, Perkins G, Kirilova A, Allen C, Jaffray DA. Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications. Invest Radiol 2006; 41(3): 339-348. (Pubitemid 44406196)
8. Zheng J, Liu J, Dunne M, Jaffray DA, Allen C. In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res 2007; 24(6): 1193-1201.
9. Zheng J, Jaffray DA, Allen C. Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model. Mol Pharm 2009; Mar-Apr; 6: 571-580.
10. Misselwitz B, Sachse A. Interstitial MR lymphography using Gd-carrying liposomes. Acta Radiol Suppl 1997; 412: 51-55. (Pubitemid 127619162)
11. Silverman PM. Liver metastases: imaging considerations for protocol development with multislice CT (MSCT). Cancer Imag 2006; 6: 175-181.
12. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65(1-2): 271-284.
13. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4(2): 145-160.
14. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 1999; 37(1-3): 225-235.
15. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989; 6(3): 193-210.
16. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995; 31(5): 766-770.
17. Laverman P, Dams ET, Storm G, Hafmans TG, Croes HJ, Oyen WJ, Corstens FH, Boerman OC. Microscopic localization of PEG-liposomes in a rat model of focal infection. J Control Release 2001; 75(3): 347-355.
18. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, Hricak H, Klimstra D, Fong Y. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007; 48(5): 771-775.
19. Guo H, Zhu H, Xi Y, Zhang B, Li L, Huang Y, Zhang J, Fu Z, Yang G, Yuan S, Yu J. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med 2007; 48(8): 1251-1258.
20. Hamazawa Y, Koyama K, Okamura T, Wada Y, Wakasa T, Okuma T, Watanabe Y, Inoue Y. Comparison of dynamic FDG-microPET study in a rabbit turpentine-induced inflammatory model and in a rabbit VX2 tumor model. Ann Nucl Med 2007; 21(1): 47-55. (Pubitemid 46280149)
21. Ogihara I, Kojima S, Jay M. Differential uptake of gallium-67-labeled liposomes between tumors and inflammatory lesions in rats. J Nucl Med 1986; 27(8): 1300-1307. (Pubitemid 17030126)
22. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 2005; 46(11): 1819-1824.
23. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, Alavi A. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26(10): 1345-1348. (Pubitemid 29467031)
24. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18- fluorodeoxyglucose uptake. J Nucl Med 1994; 35(1): 104-112. (Pubitemid 24018451)
25. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33(11): 1972-1980.
26. Graves DT, Valente AJ. Monocyte chemotactic proteins from human tumor cells. Biochem Pharmacol 1991; 41(3): 333-337.
27. Steele RJ, Brown M, Eremin O. Characterisation of macrophages infiltrating human mammary carcinomas. Br J Cancer 1985; 51(1): 135-138. (Pubitemid 15151700)
28. Kaim AH, Weber B, Kurrer MO, Gottschalk J, Von Schulthess GK, Buck A. Autoradiographic quantification of 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology 2002; 223(2): 446-451. (Pubitemid 34454324)
29. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52(19): 5135-5143.
30. de Crespigny AJ, Howard D, D'Arceuil H, Muller H, Agoston AT, Seri S, Hashiguchi Y, Fujimoto C, Nakatani A, Moseley ME. Dynamic contrast-enhanced MRI of Implanted VX2 tumors in rabbit muscle: comparison of Gd-DTPA and NMS60. Magn Reson Imag 1999; 17(9): 1297-1305.
31. Park KS, Choi BI, Won HJ, Seo JB, Kim SH, Kim TK, Han JK, Yeon KM. Intratumoral vascularity of experimentally induced VX2 carcinoma: comparison of color Doppler sonography, power Doppler sonography, and microangiography. Invest Radiol 1998; 33(1): 39-44.
32. Yamada K, Jinbo T, Miyahara K, Sato M, Hirose T, Kato H, Tateno Y, Ikehira H, Sugihara H, Furuhama K. Contrast-enhanced MRI with gadodiamide injection in rabbit carcinoma models. J Vet Med Sci 1996; 58(5): 389-396. (Pubitemid 126467446)
33. Choi BI, Lee DH, Han MC. Necrotic areas in VX2 carcinoma of rabbits. Correlation of magnetic resonance imaging and pathologic appearance. Invest Radiol 1993; 28(1): 33-38.
34. Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 2009; 193(4): 1124-1127.
35. Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003; 227(3): 817-824.
36. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48(6): 932-945.